Abstract
Mycoplasma pneumoniae pneumonia (MPP) in children has experienced a global resurgence following the COVID-19 pandemic, which has been associated with more severe and/or refractory cases. Simultaneously, macrolide-resistant strains have emerged in recent decades. This new reality has increased the risk to pediatric patients and is testing the healthcare system's response. In this context, artificial intelligence (AI) is emerging as an aid or complement to the work of physicians treating children with MPP. Unfortunately, the scientific evidence regarding the contribution of AI to MPP is still limited. This manuscript compiles the most relevant studies that demonstrate that AI could be successfully applied to support diagnosis, predict severity, and assess the response to certain treatments.
Keywords
Artificial intelligence, Pneumonia, Mycoplasma pneumoniae, Children